Clobetasol
- PDF / 169,827 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 36 Downloads / 148 Views
1 S
Squamous cell carcinoma of skin: case report A 66-year- old man developed squamous cell carcinoma of skin following treatment with clobetasol for sarcoidosis. The man presented to a dermatology department with rapidly enlarging nodule at the right post-auricular area presenting over several weeks. The nodule developed within a plaque of pre-existing cutaneous sarcoidosis. In 2015, he was diagnosed with multisystem sarcoidosis, affecting both the lungs and skin. The sarcoidosis was treated with topical clobetasol [clobetasol propionate; dosage not stated], and the plaque size was reduced. He had a history of moderate sun exposure and his skin was Fitzpatrick skin type II. During the current presentation, biopsy of the nodule revealed appearances consistent with primary cutaneous squamous cell carcinoma. The man underwent formal excision of the whole skin lesion. Histology showed a poorly differentiated squamous cell carcinoma with perineural invasion and infiltration to subcutaneous tissue. A lymph node in the deep tissue was involved with an extracapsular spread. Subsequently, he underwent further wider excision with neck dissection and he had additional involvement of a lymph node without extracapsular spread. The carcinoma was staged at UICC TNM8 pT3 PN3b. Neck, chest and abdominal CT did not show any metastases but confirmed persistent mediastinal and abdominal lymphadenopathy. Later, he received adjuvant radiotherapy to the site. It was reported that the Immunosuppression by clobetasol had attributed for the squamous cell carcinoma of skin [duration of treatment to reaction onset and outcome not stated]. Lim PN, et al. Presentation of squamous cell carcinoma in pre-existing cutaneous sarcoidosis. BMJ Case Reports 13: e236426, No. 8, 24 Aug 2020. Available from: URL: 803506066 http://doi.org/10.1136/bcr-2020-236426
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
